Eileen Parkes, MD, PhD

ONCOLOGY recently interviewed Dr. Eileen Parkes, whose laboratory studies the STING pathway, to find out why researchers are excited about targeting this pathway as a potential cancer therapy.

Late last year, ONCOLOGY hosted a writing contest on CancerNetwork.com, in which we asked our readers to share their personal experiences with delivering bad news. The essay by Dr. Eileen Parkes from Queen’s University Belfast, United Kingdom, was selected as the first place winner.